Cargando…

Correction: Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515467/ https://www.ncbi.nlm.nih.gov/pubmed/34645677 http://dx.doi.org/10.1136/jitc-2020-001895corr1

Ejemplares similares

Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
por: Liu, Chao, et al.
Publicado: (2021)

Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer
por: Pecci, Federica, et al.
Publicado: (2021)

Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
por: Ghiringhelli, François, et al.
Publicado: (2019)

Correction: Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy
por: Liu, Can, et al.
Publicado: (2019)

Correction: CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
Publicado: (2022)

Correction: Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
Publicado: (2022)

Correction: Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1- immunotherapy in colon cancer
Publicado: (2021)

Correction to: Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
por: Brogden, Kim A., et al.
Publicado: (2018)

Correction to: A gene expression assay for simultaneous measurement of microsatellite instability and anti-tumor immune activity
por: Danaher, Patrick, et al.
Publicado: (2019)

Radiation Therapy Enhances Immunotherapy Response in Microsatellite-stable Colorectal and Pancreatic Adenocarcinoma in a Phase II Trial
por: Parikh, Aparna R., et al.
Publicado: (2021)

Correction To: Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer
por: Gao, Yaohui, et al.
Publicado: (2021)

Author Correction: Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
por: Li, Maohua, et al.
Publicado: (2022)

Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer
por: Kim, Chang Woo, et al.
Publicado: (2021)

The role of immunotherapy in microsatellites stable metastatic colorectal cancer: state of the art and future perspectives
por: Gandini, Annalice, et al.
Publicado: (2023)

Correction to: Serum CCL20 combined with IL-17A as early diagnostic and prognostic biomarkers for human colorectal cancer
por: Wang, Dan, et al.
Publicado: (2021)

Correction to: Inhibition of autophagy enhances synergistic effects of Salidroside and anti-tumor agents against colorectal cancer
por: Li, Hai, et al.
Publicado: (2018)

Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

Correction: Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
por: Chu, Xianjing, et al.
Publicado: (2023)

Publisher Correction: Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy
por: Haikala, Heidi M., et al.
Publicado: (2019)

Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial
por: Qin, Shukui, et al.
Publicado: (2022)

Correction: Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model
Publicado: (2023)

Correction: Estradiol Enhances CD4(+) T-Cell Anti-Viral Immunity by Priming Vaginal DCs to Induce T(h)17 Responses via an IL-1-Dependent Pathway
por: Anipindi, Varun C., et al.
Publicado: (2016)

The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Retrospective Study
por: Li, Jisheng, et al.
Publicado: (2020)

Correction to: Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
por: Wakabayashi, Grace, et al.
Publicado: (2019)

The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers
por: Wang, Qiao-Xuan, et al.
Publicado: (2021)

Correction to: Tumor-associated neutrophils induce EMT by IL-17a to promote migration and invasion in gastric cancer cells
por: Li, Sen, et al.
Publicado: (2019)

Correction: Correlation of Chromosomal Instability, Telomere Length and Telomere Maintenance in Microsatellite Stable Rectal Cancer: A Molecular Subclass of Rectal Cancer
Publicado: (2014)

Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine
por: Huyghe, Nicolas, et al.
Publicado: (2022)

Correction: Neutrophils Are Essential As A Source Of Il-17 In The Effector Phase Of Arthritis
por: Katayama, Masaki, et al.
Publicado: (2013)

Correction: HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo
por: Booth, Laurence, et al.
Publicado: (2019)

Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
por: Doleschel, Dennis, et al.
Publicado: (2021)

Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
por: Johnson, Benny, et al.
Publicado: (2022)

Correction: Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy
por: Fumet, Jean-David, et al.
Publicado: (2019)

Opportunities for immunotherapy in microsatellite instable colorectal cancer
por: Westdorp, Harm, et al.
Publicado: (2016)

The expressed mutational landscape of microsatellite stable colorectal cancers
por: Sveen, Anita, et al.
Publicado: (2021)

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
por: Zhao, Pengfei, et al.
Publicado: (2019)

Correction: Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1
Publicado: (2023)

Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy
por: Tu, Megan M., et al.
Publicado: (2019)

Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma
por: Shi, Guilan, et al.
Publicado: (2022)

Homologous Recombination Repair Truncations Predict Hypermutation in Microsatellite Stable Colorectal and Endometrial Tumors
por: Lee, Minyi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qch6j3bg2vavlbsmdh3st3d0up